Submit to Cancers Review for Cancers Propose a Special Issue

Journal Menu

Journal Browser

Special Issue "Quality of Life in Patients with Gynecologic Cancer"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Survivorship and Quality of Life".

Deadline for manuscript submissions: closed (15 November 2023) | Viewed by 2704

Share This Special Issue

Special Issue Editor

Prof. Dr. Jalid Sehouli

E-Mail Website
Guest Editor

Department of Gynecology with Center for Oncological Surgery, Virchow Campus Clinic, Charité Medical University, Augustenburger Platz 1, 13353 Berlin, Germany
Interests: cervical cancer; endometriosis prevention; gynecologic oncology; gynecological surgery; cancer chemotherapy; cancer immunotherapy; cancer care facilities; ovarian cancer

Special Issue Information

Dear Colleagues,

Quality of life (QoL) has become one of the most relevant goals and endpoints in gynecological cancer management, taking into consideration the patient’s perspective to support the treatment decision-making process. This Special Issue attempts to highlight this relevant endpoint with the aim of increasing the awareness of this topic in clinical practice. For this reason, we hope to include articles from patient perspectives, as well as from doctor perspectives in taboo fields, including sexuality and end-of-life management. Furthermore, in general, quality of life issues are neglected in the increasingly more relevant space of long-term survivorship.

Prof. Dr. Jalid Sehouli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

quality of life
gynecologic oncology
advanced directives
sexuality
art therapy
breaking bad news

Published Papers (3 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

12 pages, 948 KiB

Open AccessArticle

Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey

Cancers 2023, 15(22), 5428; https://doi.org/10.3390/cancers15225428 - 15 Nov 2023

Viewed by 602

Abstract

The aim of this survey was to increase the knowledge on the characteristics and health concerns of long-term survivors (LTS; survival > 5 years) after ovarian cancer in order to tailor follow-up care. This international survey was initiated by the NOGGO and was made available to members of ENGOT and GCIG. The survey is anonymous and consists of 68 questions regarding sociodemographic, medical (cancer) history, health concerns including distress, long-term side effects, and lifestyle. For this analysis, 1044 LTS from 14 countries were recruited. In total, 58% were diagnosed with FIGO stage III/IV ovarian cancer and 43.4% developed recurrent disease, while 26.0% were receiving cancer treatment at the time of filling in the survey. LTS who survived 5–10 years self-estimated their health status as being significantly worse than LTS who survived more than 10 years (p = 0.034), whereas distress also remained high 10 years after cancer diagnosis. Almost half of the cohort (46.1%) reported still having symptoms, which were mainly lymphedema (37.7%), fatigue (23.9%), pain (21.6%), polyneuropathy (16.9%), gastrointestinal problems (16.6%), and memory problems (15.5%). Almost all patients (94.2%) regularly received follow-up care. Specialized survivorship care with a focus on long-term side effects, lifestyle, and prevention should be offered beyond the typical five years of follow-up care. Full article

(This article belongs to the Special Issue Quality of Life in Patients with Gynecologic Cancer)

► Show Figures

Figure 1

13 pages, 1262 KiB

Open AccessArticle

Cytoreductive Surgery with the PlasmaJet Improved Quality-of-Life for Advanced Stage Ovarian Cancer Patients

Gatske M. Nieuwenhuyzen-de Boer

Hanane Aamran

Caroline B. van den Berg

Sten Willemsen

Jurgen M. J. Piek

Nathalie Reesink-Peters

Marianne Maliepaard

Helena C. van Doorn

Suzanne Polinder

and

Heleen J. van Beekhuizen

Cancers 2023, 15(15), 3947; https://doi.org/10.3390/cancers15153947 - 03 Aug 2023

Viewed by 612

Abstract

Background: Knowledge of quality-of-life after cytoreductive surgery is important to counsel patients with advanced-stage epithelial ovarian cancer prior to surgery. The aim of this study was to determine whether the use of the PlasmaJet Surgical device during cytoreductive surgery has an effect on the quality-of-life of patients with advanced epithelial ovarian cancer. Methods: Data included in this prospective observational study were derived from the PlaComOv study, in which patients with advanced epithelial ovarian cancer were randomly assigned to have cytoreductive surgery with or without adjuvant use of the PlasmaJet. Quality-of-life was measured before surgery and one, six, 12, and 24 months after surgery with three questionnaires: the EORTC QLQ-C30, QLQ-OV28, and EQ-5D-5L. Results: Between 2018 and 2020, 326 patients were enrolled in the trial. The overall response rate was high, with the lowest response rate at 24 months of 77%. At 6 months, quality-of-life was higher in the intervention group (95%CI 0.009; 0.081, p = 0.045). At 12 months, quality-of-life was higher in the intervention group with fewer symptoms of fatigue, appetite loss, and diarrhea (95%CI 0.6; 10,0, p = 0.027); similarly, patients in the intervention group reported a better body image (95%CI −14.2; −3.0, p = 0.003) and a higher score on the visual analog scale (95%CI 1.99; 11.15, p = 0.005). At 24 months postoperatively, no further difference was found between the two groups except for pain (95%CI −12.9; −0.8, p = 0.027) and body image (95%CI −13.808; −0.733, p = 0.029). A higher quality-of-life in the intervention group was partially explained by the mediator ‘surgery outcome’. Conclusions: This study demonstrated knowledge of patients’ quality-of-life until two years after cytoreductive surgery. The use of the PlasmaJet Surgical device during cytoreductive surgery leads to a higher quality-of-life than conventional surgery with electrocoagulation alone. Even after adjustment for the mediator of surgical outcome, a higher quality-of-life was seen in patients who had surgery with the use of the PlasmaJet device. Full article

(This article belongs to the Special Issue Quality of Life in Patients with Gynecologic Cancer)

► Show Figures

Figure 1

9 pages, 1173 KiB

Open AccessArticle

Patient-Reported Mobility, Physical Activity, and Bicycle Use after Vulvar Carcinoma Surgery

Nick J. van de Berg

Franciscus P. van Beurden

G. C. Wanda Wendel-Vos

Marjolein Duijvestijn

Heleen J. van Beekhuizen

Marianne Maliepaard

and

Helena C. van Doorn

Cancers 2023, 15(8), 2324; https://doi.org/10.3390/cancers15082324 - 16 Apr 2023

Viewed by 1130

Abstract

Patients treated for vulvar carcinoma may experience losses in mobility and physical activity. In this study, we assess the prevalence and severity of mobility problems using patient-reported outcomes of three questionnaires: EQ-5D-5L to estimate QoL and perceived health; SQUASH to estimate habitual physical activity; and a problem-specific questionnaire on bicycling. Patients treated for vulvar carcinoma between 2018 and 2021 were recruited, and 84 (62.7%) responded. The mean age was 68 ± 12 years (mean ± standard deviation). Self-reported QoL and perceived health were 0.832 ± 0.224 and 75.6 ± 20.0, respectively. Dutch physical activity guidelines were met by 34.2% of participants. Compared to baseline values, the times spent walking, bicycling, and participating in sports were all reduced. During bicycling, patients experienced moderate or severe pain in the skin of the vulva (24.5%), pain in the sit bones (23.2%), chafing (25.5%), or itching (8.9%). Overall, 40.3% experienced moderate or severe bicycling problems or could not bicycle, 34.9% felt that their vulva impeded bicycling, and 57.1% wished to make more or longer bicycling journeys. To conclude, vulvar carcinoma and its treatment reduce self-reported health, mobility, and physical activity. This motivates us to investigate ways to reduce discomfort during physical activities, and help women regain their mobility and self-reliance. Full article

(This article belongs to the Special Issue Quality of Life in Patients with Gynecologic Cancer)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Quality of Life in Patients with Gynecologic Cancer"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (3 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI